IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Holdings in Recursion Pharmaceuticals, Inc. $RXRX

IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 135.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 911,085 shares of the company’s stock after buying an additional 523,848 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd owned about 0.22% of Recursion Pharmaceuticals worth $4,610,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in RXRX. Clear Creek Financial Management LLC increased its stake in Recursion Pharmaceuticals by 9.8% during the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company’s stock worth $113,000 after acquiring an additional 1,907 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after purchasing an additional 2,026 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Recursion Pharmaceuticals by 16.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,439 shares of the company’s stock worth $78,000 after purchasing an additional 2,219 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Recursion Pharmaceuticals by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 30,864 shares of the company’s stock worth $163,000 after purchasing an additional 2,587 shares during the last quarter. Finally, Rafferty Asset Management LLC raised its holdings in Recursion Pharmaceuticals by 0.5% in the 1st quarter. Rafferty Asset Management LLC now owns 598,420 shares of the company’s stock valued at $3,166,000 after buying an additional 2,948 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Trading Up 4.3%

NASDAQ RXRX opened at $6.30 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -3.54 and a beta of 0.91. The firm has a 50 day simple moving average of $5.19 and a 200-day simple moving average of $5.20. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The business had revenue of $19.10 million for the quarter, compared to analysts’ expectations of $15.38 million. During the same period in the previous year, the company earned ($0.40) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was up 33.3% on a year-over-year basis. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the sale, the insider directly owned 668,197 shares in the company, valued at approximately $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 8.43% of the company’s stock.

Analyst Upgrades and Downgrades

RXRX has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.